FDA Fast Track Designation
MavriX Bio announced that that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MVX-220, an investigational adeno-associated virus (AAV) gene therapy for the treatment of Angelman syndrome. Read the press release.
New Clinical Trial
ASCEND-AS is now listed on ClinicalTrials.gov, a Phase 1/2 first-in-human clinical study of MVX-220 in Angelman syndrome that will evaluate safety and tolerability as well as clinical efficacy assessments. (Clinicaltrials.gov ID: NCT07181837)
MVX-220 Webinar
A community webinar will be held on October 9, 2025 at 1pm ET. This webinar will be jointly hosted by FAST and ASF to provide details about the upcoming trial. MavriX will provide a summary of the trial design, requirements, and enrollment criteria.
Register for the webinar and submit your questions: https://us02web.zoom.us/webinar/register/WN_YgtRsvq6QTWNgs4sSW7yxA